New Chimeric Engulfing Receptor T Cells From CERo Therapeutics Show Multifunctional Properties and Improved Tumor Killing


[ad_1]

First data presented at SITC 2021 demonstrate target-dependent cytotoxic function as well as innate immune functions of antigen uptake and APC-like activity

Multifunctionality suggests potential for improved tumor clearance and durability of response compared to existing cell therapies

SUD SAN FRANCISCO, California, November 12, 2021– (COMMERCIAL THREAD) – CERo Therapeutics, Inc., a pioneering biopharmaceutical company in the development of novel autologous modified immune cell therapies, today presented the results of preclinical studies in vitro studies describing the characterization of novel chimeric engulfing receptor (CER) T cells. CERs are genetically engineered proteins that bind to inducible, agnostic stress ligands on the surface of tumor cells to induce tumor-specific cytotoxicity and innate immune functions such as engulfment and antigen presentation. The data, which is presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021), demonstrates that T cells engineered to express CERs exhibit multifunctional properties of innate and adaptive immune responses and suggest the potential of cells T CER. to overcome the barriers associated with existing adoptive cell therapies.

“These studies demonstrate for the first time the unique orthogonal profile of CER T cells to combine the clearance attributes of tumor cells from macrophages and dendritic cells of the innate immune system with activation of T cells from the adoptive immune system in a only modified T cell. ”said Daniel Corey, MD, founder and CEO of CERo. “One of the limitations of activated T cells is their poor ability to present antigens due to inefficient antigen uptake. In contrast, CER T cells facilitate antigen uptake, processing and presentation. and confer target-dependent cytokine function, thus providing a possible means of improving the therapeutic potential of modified cell therapies. “

In studies, CER T cell constructs containing an extracellular phagocytic receptor were characterized for multiple functions, including cytotoxicity in combination with Bruton’s tyrosine kinase inhibitor (BTKi), uptake of tumor cell fragments , T cell activation, cytokine induction and presentation of antigen cell-type activity (APC). The results of these in vitro studies have shown that CER T cells synergize with BTKi to enhance destruction of a mantle cell lymphoma tumor cell line. In addition, CER T cells have shown abilities to capture tumor cell fragments and induce expression of T cell activation markers and cytokines. CER T cells containing a Toll-like receptor domain (TLR) have also shown an increased ability to present exogenous antigen and activate antigen-specific TCR T cells.

The poster titled “Enhanced antigen capture, antigen-presenting cell (APC) -like function, and cytotoxic response with chimeric engulfment receptor (CER) T cells” (Abstract # 207) is now available virtually via the SITC website and in person today from 7 a.m. to 8:30 p.m. ET in Exhibit Hall E.

About CERo’s platform technology

CERo’s technology aims to extend the therapeutic potential of modified T cell therapies by introducing distinct and complementary tumor cell clearance pathways into a single T cell. By designing T cells to express CERs, the technology of the CERo platform enables T cells to target tumors, induce cell damage, engulf tumor fragments, and eliminate tumors, effectively harnessing the anti-tumor attributes of innate and adaptive immune responses. CER T cell products are designed to generate a more complete and lasting anti-tumor response. This new biology is suitable for combinations with conventional CAR T cell or small molecule therapy and has potential applications in hematologic malignancies and solid tumors.

About CERo Therapeutics

CERo Therapeutics, Inc. is a biopharmaceutical company pioneering a new class of cell therapies that combine the attributes of the innate and adaptive arms of the immune system into unique T cells. The integrated approach builds on recent advances in synthetic biology and T lymphocytes with the aim of improving and optimizing cell therapy in order to increase the curative potential and safety profile of current approaches. CERo is advancing a pipeline of CER T cell products designed against hematologic malignancies and solid tumors. To learn more about the company and its science, please visit www.cero.bio.

View the source version on businesswire.com: https://www.businesswire.com/news/home/2021112005008/en/

Contacts

Lindy Devereux
Scientific PR
646-515-5730
[email protected]

[ad_2]

Comments are closed.